Antibiotic-enriched Platelet-Rich Fibrin (PRF)

Preclinical

Antibiotic-enriched Platelet-Rich Fibrin (PRF) is one of 2 therapeutic programs targeting Facial Swelling. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Facial SwellingActive, not recruiting

Facial SwellingPreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Facial Swelling

#DrugCompanyPhaseTrials

Platelet-Rich Fibrin (PRF)

FFederal University of São Paulo

Preclinical

1 2

Antibiotic-enriched Platelet-Rich Fibrin (PRF)

AAmerigo Giudice

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Facial Swelling

NCT07764757

Clinical

Trials by Indication[1]

Facial Swelling1 trial

Effects of Antibiotic-Prepared Platelet-Rich Fibrin on Postoperative Recovery After Mandibular Third Molar Surgery: A Randomized Split-Mouth Clinical Trial

Active, not recruiting·AAmerigo Giudice·Preclinical·NCT07764757·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antibiotic-enriched Platelet-Rich Fibrin (PRF). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Antibiotic-enriched Platelet-Rich Fibrin (PRF). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Amerigo Giudice company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: AAmerigo Giudice

Antibiotic-enriched Platelet-Rich Fibrin (PRF)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Facial Swelling1 trial

References

Drug Info

Quick Facts

Related News